Alumis adds lonigutamab and ~$486M liquidity via ACELYRIN merger; heavy R&D burn fuels losses

Snapshot - Alumis Inc. (NASDAQ: ALMS)
What's happening inside: management completed the ACELYRIN merger (closed May 21, 2025), added lonigutamab and ~ $238.1M of equity consideration, materially strengthened liquid resources, but is simultaneously ramping R&D and integration costs that drove substantial operating losses and heavy cash burn in H1 2025.

Key points & statistics (from 10‑Q, quarter ended June 30, 2025)
* Total assets: $610,925,000 (June 30, 2025).
* Cash & cash equivalents: $151,753,000; marketable securities: $334,568,000 → cash + marketable securities ≈ $486.3M (June 30, 2025).
* Total liabilities: $125,598,000; total stockholders' equity: $485,327,000.
* Revenue: Q2 2025 $2,666,000; YTD 6‑month 2025 $20,055,000 (includes $17,389,000 license revenue from Kaken).
* R&D expense: Q2 2025 $108,755,000; 6‑month 2025 $205,377,000 (vs. $48,565K and $90,526K in prior periods).
* G&A expense: Q2 2025 $34,450,000; 6‑month 2025 $56,745,000 (big increase vs. prior year).
* Loss from operations: Q2 2025 $(140,539,000); 6‑month 2025 $(242,067,000).
* Other income: gain on bargain purchase (ACELYRIN Merger) $187,907,000 recorded in Q2 2025.
* Net income (loss): Q2 2025 net income $59,321,000 (driven by bargain purchase gain); 6‑month 2025 net loss $(39,642,000).
* Cash used in operating activities (6 months): $(186,707,000).
* Accumulated deficit: $(698,193,000) (June 30, 2025).
* Shares: issued common stock (total) 104,042,477 (per equity table at June 30, 2025); as of Aug 7, 2025 the company reported 96,879,394 voting and 7,184,908 non‑voting shares outstanding.
* EPS (basic): Q2 2025 $0.78; 6‑month 2025 $(0.61).
* Acquired intangible (IPR&D) asset related to lonigutamab: $50,959,000 (preliminary fair value).

Income statement - positives
* Kaken collaboration delivered upfront and committed development funding: $20.0M upfront; the company recognized $17.4M of license revenue in H1 2025 and expects cost‑reimbursements through 2026 - meaningful non‑dilutive near‑term cash.
* ACELYRIN Merger produced a one‑time gain on bargain purchase of $187.9M (accounting gain) which turned Q2 into a reported net income quarter.
* Interest income rose as cash/investments increased: Q2 interest income $3,430,000 (vs. $1,977,000 prior year quarter).
* Strong liquid position post‑merger: ~$486.3M in cash + marketable securities gives management runway (they state ≥12 months from filing date).

Income statement - negatives / concerns
* Heavy operating expense ramp: R&D + G&A = $262.1M in H1 2025 (vs. $103.7M prior year) - large and accelerating burn driven by trial progression, ACELYRIN integration and severance/transaction costs.
* Cash flow from operations is negative and large: $(186.7)M used in operations in six months - merger cash injection helped investing cash flow but operating burn is the structural risk.
* Reported quarterly net income is driven by an accounting gain (bargain purchase). Underlying operations remain loss‑making - H1 net loss $(39.6)M.
* Stock‑based compensation and share count increased materially (dilution risk); unrecognized stock‑based comp ≈ $62.0M to be expensed over ~2.5 years (per note).
* Accumulated deficit nearly $700M and significant milestone/contingent liabilities remain (see risk items below).

Balance sheet / liquidity highlights & obligations
* Short term liquidity: cash & marketable securities ≈ $486.3M (June 30, 2025). Management: "sufficient to meet operating and capital requirements for at least 12 months."
* Total assets: $610.9M; shareholders' equity: $485.3M.
* Operating lease liabilities (total): $38,776,000 (present value) and undiscounted future lease payments $56,921,000.
* Contingent / milestone exposure: Pierre Fabre agreement obligates up to ~$100.5M in development/regulatory milestones + up to $390M in commercial milestones and tiered royalties (total potential payouts disclosed in notes).
* FronThera contingent consideration: up to $120.0M (milestones - some already paid historically).
* Severance, integration, and stock‑comp charges tied to ACELYRIN Merger: management recognized transaction costs and expects additional stock‑based compensation to be recognized.

Operational & strategic notes
* ACELYRIN Merger (closed May 21, 2025): issued 48,653,549 shares (prelim purchase consideration $238,077K); recognized net assets fair value $426.0M and $187.9M gain on bargain purchase (prelim). ACELYRIN added lonigutamab (IPR&D $50.959M), cash, and marketable securities.
* Clinical pipeline: envudeucitinib ("envu") - Phase 3 ONWARD program underway for psoriasis; Phase 2b ongoing in SLE (topline expected Q3 2026 per MD&A). A‑005 development (CNS penetrant TYK2) progressing (Phase 1 started 2024).
* Revenue mix: currently collaboration/licensing and development reimbursements; no product sales yet.
* Legal / contingent risks: ACELYRIN‑era securities class action pending (Boukadoum v. Acelyrin); company disclosed other legal and contingent liabilities in the filing.
* Management view: will need additional capital over time, plans include equity, debt, strategic alliances or licensing; runway depends on pace of trials and potential milestone receipts.

Bottom line - what's happening inside the company
Alumis (NASDAQ: ALMS) is in heavy investment mode. Management used the ACELYRIN merger to add product assets (lonigutamab), cash and marketable securities and reported a one‑time accounting gain that produced positive GAAP income this quarter. At the same time the company is scaling clinical programs (Phase 3 for envu), absorbing merger integration and severance costs, and running an elevated R&D budget that produced large operating losses and $186.7M of cash burn in H1 2025. The near‑term balance sheet looks comfortable (≈$486M liquidity and management expects ≥12 months runway), but the business is capital intensive and reliant on trial progress, milestone payments and future financing or partnerships to fund continuing development and potential commercialization.

Investor takeaway (straightforward)
* Positive: materially stronger liquidity and added product/IP through the ACELYRIN deal; meaningful collaboration cash (Kaken) and a healthy investment portfolio.
* Negative: underlying operations are cash‑consumptive - R&D and G&A have jumped dramatically; GAAP net income this quarter is driven by a non‑recurring accounting gain, not operating profits.
* Conclusion: company is deep into clinical development and integration. Watch cash burn vs. runway, milestone receipts, clinical readouts (envu Phase 3 and SLE), and any further financing or partnership moves. Short‑term balance sheet comfort exists; medium‑term value depends on trial outcomes and ability to manage spending or secure non‑dilutive funding.

If you want, I can prepare a 1‑page executive summary for investors, a short risks checklist, or a focused briefing on the ACELYRIN merger accounting and near‑term cash runway.